UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 28

Sortiert nach

Selexipag for the Treatment of Pulmonary Arterial Hypertension

The New England journal of medicine, 2015-12, Vol.373 (26), p.2522-2533

2015

Volltextzugriff (PDF)

Safety and tolerability of transition from inhaled treprostinil to oral selexipag in pulmonary arterial hypertension: Results from the TRANSIT-1 study

The Journal of heart and lung transplantation, 2019-01, Vol.38 (1), p.43-50

2019

Volltextzugriff (PDF)

The right ventricle in pulmonary hypertension

Coronary artery disease, 2005-02, Vol.16 (1), p.13-18

2005

Volltextzugriff (PDF)

Pregnancy and Congenital Heart Disease-Associated Pulmonary Hypertension: Are Outcomes Improving?

Circulation (New York, N.Y.), 2023-02, Vol.147 (7), p.562-564

2023

Volltextzugriff (PDF)

Temporarily switching from oral to intravenous selexipag in patients with pulmonary arterial hypertension: safety, tolerability, and pharmacokinetic results from an open-label, phase III study

Respiratory research, 2021-02, Vol.22 (1), p.34-9, Article 34

2021

Volltextzugriff (PDF)

Macitentan in Pulmonary Arterial Hypertension Associated with Connective Tissue Disease (CTD-PAH): Real-World Evidence from the Combined OPUS/OrPHeUS Dataset

Cardiology and therapy, 2024-06, Vol.13 (2), p.315-339

2024

Volltextzugriff (PDF)

Safety of Macitentan for the Treatment of Portopulmonary Hypertension: Real-World Evidence from the Combined OPUS/OrPHeUS Studies

Pulmonary therapy, 2024-03, Vol.10 (1), p.85-107

2024

Volltextzugriff (PDF)

Three- Versus Two-Drug Therapy for Patients With Newly Diagnosed Pulmonary Arterial Hypertension

Journal of the American College of Cardiology, 2021-10, Vol.78 (14), p.1393-1403

2021

Volltextzugriff (PDF)

Prognosis of pulmonary arterial hypertension patients with pericardial effusion before and after initiation of parenteral prostacyclin therapy

Pulmonary circulation, 2023-04, Vol.13 (2), p.e12226-n/a

2023

Volltextzugriff (PDF)

Safety of macitentan for the treatment of pulmonary hypertension: Real‐world experience from the OPsumit® USers Registry (OPUS) and OPsumit® Historical USers cohort (OrPHeUS)

Pulmonary circulation, 2022-10, Vol.12 (4), p.e12150-n/a

2022

Volltextzugriff (PDF)

Pulmonary Arterial Hypertension—Symptoms and Impact Questionnaire: feasibility of utilizing one-day versus seven-day symptom reporting

Pulmonary circulation, 2020-04, Vol.10 (2), p.1-9

2020

Volltextzugriff (PDF)

Randomized Trial of Macitentan/Tadalafil Single-Tablet Combination Therapy for Pulmonary Arterial Hypertension

Journal of the American College of Cardiology, 2024-01, Vol.83 (4), p.473-484

2024

Volltextzugriff (PDF)

Prognostic Value of Echocardiographic Variables Prior to and Following Initiation of Parenteral Prostacyclin Therapy: An Observational Study

Chest, 2022-09, Vol.162 (3), p.669-683

2022

Volltextzugriff (PDF)

The impact of comorbidities on selexipag treatment effect in patients with pulmonary arterial hypertension: insights from the GRIPHON study

European journal of heart failure, 2022-01, Vol.24 (1), p.205-214

2022

Volltextzugriff (PDF)

Relationship Between Time From Diagnosis and Morbidity or Mortality in Pulmonary Arterial Hypertension: Results From the Phase III GRIPHON Study

Chest, 2021-07, Vol.160 (1), p.277-286

2021

Volltextzugriff (PDF)

Mortality in Patients With Pulmonary Arterial Hypertension Treated With Continuous Prostanoids

Chest, 2018-09, Vol.154 (3), p.532-540

2018

Volltextzugriff (PDF)

Selexipag treatment for pulmonary arterial hypertension associated with congenital heart disease after defect correction: insights from the randomised controlled GRIPHON study

European journal of heart failure, 2019-03, Vol.21 (3), p.352-359

2019

Volltextzugriff (PDF)

Psychometric Validation of the Pulmonary Arterial Hypertension-Symptoms and Impact (PAH-SYMPACT) Questionnaire: Results of the SYMPHONY Trial

Chest, 2018-10, Vol.154 (4), p.848-861

2018

Volltextzugriff (PDF)

Long-Term Survival, Safety and Tolerability with Selexipag in Patients with Pulmonary Arterial Hypertension: Results from GRIPHON and its Open-Label Extension

Advances in therapy, 2022-01, Vol.39 (1), p.796-810

2022

Volltextzugriff (PDF)

Selexipag in the treatment of pulmonary arterial hypertension: design, development, and therapy

Drug design, development and therapy, 2016-01, Vol.10, p.3747-3754

2016

Volltextzugriff (PDF)

Relationship Between Time From Diagnosis and Morbidity/Mortality in Pulmonary Arterial Hypertension

Chest, 2021-07, Vol.160 (1), p.277-286

2021

Volltextzugriff (PDF)

Psychometric Validation of the Pulmonary Arterial Hypertension-Symptoms and Impact (PAH-SYMPACT) Questionnaire

Chest, 2018-10, Vol.154 (4), p.848-861

2018

Volltextzugriff (PDF)

Prostacyclin administration errors in pulmonary arterial hypertension patients admitted to hospitals in the United States: a national survey

The Journal of heart and lung transplantation, 2010-08, Vol.29 (8), p.841-846

2010

Volltextzugriff (PDF)

Ambrisentan and Tadalafil Up-front Combination Therapy in Scleroderma-associated Pulmonary Arterial Hypertension

American journal of respiratory and critical care medicine, 2015-11, Vol.192 (9), p.1102-1110

2015

Volltextzugriff (PDF)

“Treat-to-close”: Non-repairable ASD-PAH in the adult

International journal of cardiology, 2019-09, Vol.291, p.127-133

2019

Volltextzugriff (PDF)

1 – 25 von 28

Suche als RSS-Feed

Aktive Filter

ThemaPulmonary Arterial Hypertension

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(28)
Mit Volltextzugriff
(27)

Publikationsform

Artikel
(28)

Sprache

Englisch
(28)
Japanisch
(5)

Erscheinungsjahr

n.n

Thema

Life Sciences & Biomedicine
(25)
Science & Technology
(25)
Cardiac & Cardiovascular Systems
(15)
Cardiovascular System & Cardiology
(15)
Humans
(14)
Respiratory System
(14)
Selexipag
(11)
Female
(8)
Hypertension, Pulmonary - Drug Therapy
(8)
Pulmonary Hypertension
(8)
Male
(7)
General & Internal Medicine
(6)
Macitentan
(6)
Middle Aged
(6)
Critical Care Medicine
(5)
Acetamides - Therapeutic Use
(4)
Antihypertensive Agents - Therapeutic Use
(4)
Clinical Trials
(4)
Double-Blind Method
(4)

14 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

Selexipag for the Treatment of Pulmonary Arterial Hypertension

Safety and tolerability of transition from inhaled treprostinil to oral selexipag in pulmonary arterial hypertension: Results from the TRANSIT-1 study

The right ventricle in pulmonary hypertension

Pregnancy and Congenital Heart Disease-Associated Pulmonary Hypertension: Are Outcomes Improving?

Temporarily switching from oral to intravenous selexipag in patients with pulmonary arterial hypertension: safety, tolerability, and pharmacokinetic results from an open-label, phase III study

Macitentan in Pulmonary Arterial Hypertension Associated with Connective Tissue Disease (CTD-PAH): Real-World Evidence from the Combined OPUS/OrPHeUS Dataset

Safety of Macitentan for the Treatment of Portopulmonary Hypertension: Real-World Evidence from the Combined OPUS/OrPHeUS Studies

Three- Versus Two-Drug Therapy for Patients With Newly Diagnosed Pulmonary Arterial Hypertension

Prognosis of pulmonary arterial hypertension patients with pericardial effusion before and after initiation of parenteral prostacyclin therapy

Safety of macitentan for the treatment of pulmonary hypertension: Real‐world experience from the OPsumit® USers Registry (OPUS) and OPsumit® Historical USers cohort (OrPHeUS)

Pulmonary Arterial Hypertension—Symptoms and Impact Questionnaire: feasibility of utilizing one-day versus seven-day symptom reporting

Randomized Trial of Macitentan/Tadalafil Single-Tablet Combination Therapy for Pulmonary Arterial Hypertension

Prognostic Value of Echocardiographic Variables Prior to and Following Initiation of Parenteral Prostacyclin Therapy: An Observational Study

The impact of comorbidities on selexipag treatment effect in patients with pulmonary arterial hypertension: insights from the GRIPHON study

Relationship Between Time From Diagnosis and Morbidity or Mortality in Pulmonary Arterial Hypertension: Results From the Phase III GRIPHON Study

Mortality in Patients With Pulmonary Arterial Hypertension Treated With Continuous Prostanoids

Selexipag treatment for pulmonary arterial hypertension associated with congenital heart disease after defect correction: insights from the randomised controlled GRIPHON study

Psychometric Validation of the Pulmonary Arterial Hypertension-Symptoms and Impact (PAH-SYMPACT) Questionnaire: Results of the SYMPHONY Trial

Long-Term Survival, Safety and Tolerability with Selexipag in Patients with Pulmonary Arterial Hypertension: Results from GRIPHON and its Open-Label Extension

Selexipag in the treatment of pulmonary arterial hypertension: design, development, and therapy

Relationship Between Time From Diagnosis and Morbidity/Mortality in Pulmonary Arterial Hypertension

Psychometric Validation of the Pulmonary Arterial Hypertension-Symptoms and Impact (PAH-SYMPACT) Questionnaire

Prostacyclin administration errors in pulmonary arterial hypertension patients admitted to hospitals in the United States: a national survey

Ambrisentan and Tadalafil Up-front Combination Therapy in Scleroderma-associated Pulmonary Arterial Hypertension

“Treat-to-close”: Non-repairable ASD-PAH in the adult

Aktive Filter

Suchergebnisse filtern